1381 / 1498
Ibrutininb in Mantle cell
17.5 months estimated
median response
duration
13.9 months estimated
median progression-
free survival
115 pts with MCL
(bortezomib-naïve
n=65; bortezomib-
exposed n=50); median
age 68; median 3 (1-6)
prior therapies;
44% refractory
Wang M et al. N Engl J Med 2013; 369: 507-516.